The immunotherapy advancement targeting malignant blastomas in early childhood

Malignant blastomas develop relentlessly in all functional body organs inflicting severe health ailments in younger children. Malignant blastomas exhibit diverse clinical characteristics in compliance with their emergence in functional body organs. Surprisingly, neither of these preferred treatment...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2023-02, Vol.13, p.1015115-1015115
Main Authors: Zang, Bolun, Ding, Luyue, Liu, Linlin, Arun Kumar, Senthil, Liu, Wei, Zhou, Chongchen, Duan, Yongtao
Format: Article
Language:English
Subjects:
advanced immunotherapy
childhood
chimeric-antigen based receptor cell therapy
malignant blastomas
monoclonal antibodies
Oncology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c417t-a8ff6c127c37f251f9a483490a0fce3815a3fac41055d9cc42c7c2697ae921eb3
container_end_page 1015115
container_issue
container_start_page 1015115
container_title Frontiers in oncology
container_volume 13
creator Zang, Bolun
Ding, Luyue
Liu, Linlin
Arun Kumar, Senthil
Liu, Wei
Zhou, Chongchen
Duan, Yongtao
description Malignant blastomas develop relentlessly in all functional body organs inflicting severe health ailments in younger children. Malignant blastomas exhibit diverse clinical characteristics in compliance with their emergence in functional body organs. Surprisingly, neither of these preferred treatment types (surgery, radiotherapy, and chemotherapy) showed promise or were effective in treating malignant blastomas among child patients. N ew, innovative immunotherapeutic procedures including monoclonal antibodies and chimeric-antigen based receptor (CAR) cell therapy, coupled with the clinical study of reliable therapeutic targets and immune regulatory pathways targeting malignant blastomas, have attracted the attention of clinicians recently.
doi_str_mv 10.3389/fonc.2023.1015115
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_cbefae4f12c0459d9f0732ca721e210d</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_cbefae4f12c0459d9f0732ca721e210d</doaj_id><sourcerecordid>2783791502</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-a8ff6c127c37f251f9a483490a0fce3815a3fac41055d9cc42c7c2697ae921eb3</originalsourceid><addsrcrecordid>eNpVkUtrGzEURkVoaIKbH9BNmGU3dvW0RptCCX0EQrtJoTtxfUeaUdBIrjQO-N9nHLsh0Ubi6rtHj0PIR0ZXQrTms88JV5xysWKUKcbUGbnkXMilkeLvu1frC3JV6wOdx1pRRsV7ciHWrZaM0kvy635wTRjHXcrT4Aps9w10j5DQjS5NzQSld1NIfTNCDH2CubaJUKc8Qm1CahyUuG9wCLEbcu4-kHMPsbqr07wgf75_u7_5ubz7_eP25uvdEiXT0xJa79fIuEahPVfMG5CtkIYC9ehEyxQID3OWKtUZRMlRI18bDc5w5jZiQW6P3C7Dg92WMELZ2wzBPhdy6S2UKWB0FjfOg5OecaRSmc54qgVH0DOIM9rNrC9H1na3GV2H87sLxDfQtzspDLbPj9YY3ar5mxfk0wlQ8r-dq5MdQ0UXIySXd9Vy3QptmKKHKDtGseRai_MvxzBqD1rtQas9aLUnrXPP9ev7vXT8lyieAEZCoMg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2783791502</pqid></control><display><type>article</type><title>The immunotherapy advancement targeting malignant blastomas in early childhood</title><source>PubMed</source><creator>Zang, Bolun ; Ding, Luyue ; Liu, Linlin ; Arun Kumar, Senthil ; Liu, Wei ; Zhou, Chongchen ; Duan, Yongtao</creator><creatorcontrib>Zang, Bolun ; Ding, Luyue ; Liu, Linlin ; Arun Kumar, Senthil ; Liu, Wei ; Zhou, Chongchen ; Duan, Yongtao</creatorcontrib><description>Malignant blastomas develop relentlessly in all functional body organs inflicting severe health ailments in younger children. Malignant blastomas exhibit diverse clinical characteristics in compliance with their emergence in functional body organs. Surprisingly, neither of these preferred treatment types (surgery, radiotherapy, and chemotherapy) showed promise or were effective in treating malignant blastomas among child patients. N ew, innovative immunotherapeutic procedures including monoclonal antibodies and chimeric-antigen based receptor (CAR) cell therapy, coupled with the clinical study of reliable therapeutic targets and immune regulatory pathways targeting malignant blastomas, have attracted the attention of clinicians recently.</description><identifier>ISSN: 2234-943X</identifier><identifier>EISSN: 2234-943X</identifier><identifier>DOI: 10.3389/fonc.2023.1015115</identifier><identifier>PMID: 36874100</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>advanced immunotherapy ; childhood ; chimeric-antigen based receptor cell therapy ; malignant blastomas ; monoclonal antibodies ; Oncology</subject><ispartof>Frontiers in oncology, 2023-02, Vol.13, p.1015115-1015115</ispartof><rights>Copyright © 2023 Zang, Ding, Liu, Arun Kumar, Liu, Zhou and Duan.</rights><rights>Copyright © 2023 Zang, Ding, Liu, Arun Kumar, Liu, Zhou and Duan 2023 Zang, Ding, Liu, Arun Kumar, Liu, Zhou and Duan</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c417t-a8ff6c127c37f251f9a483490a0fce3815a3fac41055d9cc42c7c2697ae921eb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978522/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978522/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36874100$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zang, Bolun</creatorcontrib><creatorcontrib>Ding, Luyue</creatorcontrib><creatorcontrib>Liu, Linlin</creatorcontrib><creatorcontrib>Arun Kumar, Senthil</creatorcontrib><creatorcontrib>Liu, Wei</creatorcontrib><creatorcontrib>Zhou, Chongchen</creatorcontrib><creatorcontrib>Duan, Yongtao</creatorcontrib><title>The immunotherapy advancement targeting malignant blastomas in early childhood</title><title>Frontiers in oncology</title><addtitle>Front Oncol</addtitle><description>Malignant blastomas develop relentlessly in all functional body organs inflicting severe health ailments in younger children. Malignant blastomas exhibit diverse clinical characteristics in compliance with their emergence in functional body organs. Surprisingly, neither of these preferred treatment types (surgery, radiotherapy, and chemotherapy) showed promise or were effective in treating malignant blastomas among child patients. N ew, innovative immunotherapeutic procedures including monoclonal antibodies and chimeric-antigen based receptor (CAR) cell therapy, coupled with the clinical study of reliable therapeutic targets and immune regulatory pathways targeting malignant blastomas, have attracted the attention of clinicians recently.</description><subject>advanced immunotherapy</subject><subject>childhood</subject><subject>chimeric-antigen based receptor cell therapy</subject><subject>malignant blastomas</subject><subject>monoclonal antibodies</subject><subject>Oncology</subject><issn>2234-943X</issn><issn>2234-943X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkUtrGzEURkVoaIKbH9BNmGU3dvW0RptCCX0EQrtJoTtxfUeaUdBIrjQO-N9nHLsh0Ubi6rtHj0PIR0ZXQrTms88JV5xysWKUKcbUGbnkXMilkeLvu1frC3JV6wOdx1pRRsV7ciHWrZaM0kvy635wTRjHXcrT4Aps9w10j5DQjS5NzQSld1NIfTNCDH2CubaJUKc8Qm1CahyUuG9wCLEbcu4-kHMPsbqr07wgf75_u7_5ubz7_eP25uvdEiXT0xJa79fIuEahPVfMG5CtkIYC9ehEyxQID3OWKtUZRMlRI18bDc5w5jZiQW6P3C7Dg92WMELZ2wzBPhdy6S2UKWB0FjfOg5OecaRSmc54qgVH0DOIM9rNrC9H1na3GV2H87sLxDfQtzspDLbPj9YY3ar5mxfk0wlQ8r-dq5MdQ0UXIySXd9Vy3QptmKKHKDtGseRai_MvxzBqD1rtQas9aLUnrXPP9ev7vXT8lyieAEZCoMg</recordid><startdate>20230216</startdate><enddate>20230216</enddate><creator>Zang, Bolun</creator><creator>Ding, Luyue</creator><creator>Liu, Linlin</creator><creator>Arun Kumar, Senthil</creator><creator>Liu, Wei</creator><creator>Zhou, Chongchen</creator><creator>Duan, Yongtao</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230216</creationdate><title>The immunotherapy advancement targeting malignant blastomas in early childhood</title><author>Zang, Bolun ; Ding, Luyue ; Liu, Linlin ; Arun Kumar, Senthil ; Liu, Wei ; Zhou, Chongchen ; Duan, Yongtao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-a8ff6c127c37f251f9a483490a0fce3815a3fac41055d9cc42c7c2697ae921eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>advanced immunotherapy</topic><topic>childhood</topic><topic>chimeric-antigen based receptor cell therapy</topic><topic>malignant blastomas</topic><topic>monoclonal antibodies</topic><topic>Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zang, Bolun</creatorcontrib><creatorcontrib>Ding, Luyue</creatorcontrib><creatorcontrib>Liu, Linlin</creatorcontrib><creatorcontrib>Arun Kumar, Senthil</creatorcontrib><creatorcontrib>Liu, Wei</creatorcontrib><creatorcontrib>Zhou, Chongchen</creatorcontrib><creatorcontrib>Duan, Yongtao</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals(OpenAccess)</collection><jtitle>Frontiers in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zang, Bolun</au><au>Ding, Luyue</au><au>Liu, Linlin</au><au>Arun Kumar, Senthil</au><au>Liu, Wei</au><au>Zhou, Chongchen</au><au>Duan, Yongtao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The immunotherapy advancement targeting malignant blastomas in early childhood</atitle><jtitle>Frontiers in oncology</jtitle><addtitle>Front Oncol</addtitle><date>2023-02-16</date><risdate>2023</risdate><volume>13</volume><spage>1015115</spage><epage>1015115</epage><pages>1015115-1015115</pages><issn>2234-943X</issn><eissn>2234-943X</eissn><abstract>Malignant blastomas develop relentlessly in all functional body organs inflicting severe health ailments in younger children. Malignant blastomas exhibit diverse clinical characteristics in compliance with their emergence in functional body organs. Surprisingly, neither of these preferred treatment types (surgery, radiotherapy, and chemotherapy) showed promise or were effective in treating malignant blastomas among child patients. N ew, innovative immunotherapeutic procedures including monoclonal antibodies and chimeric-antigen based receptor (CAR) cell therapy, coupled with the clinical study of reliable therapeutic targets and immune regulatory pathways targeting malignant blastomas, have attracted the attention of clinicians recently.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>36874100</pmid><doi>10.3389/fonc.2023.1015115</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2234-943X
ispartof Frontiers in oncology, 2023-02, Vol.13, p.1015115-1015115
issn 2234-943X
2234-943X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_cbefae4f12c0459d9f0732ca721e210d
source PubMed
subjects advanced immunotherapy
childhood
chimeric-antigen based receptor cell therapy
malignant blastomas
monoclonal antibodies
Oncology
title The immunotherapy advancement targeting malignant blastomas in early childhood
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T20%3A37%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20immunotherapy%20advancement%20targeting%20malignant%20blastomas%20in%20early%20childhood&rft.jtitle=Frontiers%20in%20oncology&rft.au=Zang,%20Bolun&rft.date=2023-02-16&rft.volume=13&rft.spage=1015115&rft.epage=1015115&rft.pages=1015115-1015115&rft.issn=2234-943X&rft.eissn=2234-943X&rft_id=info:doi/10.3389/fonc.2023.1015115&rft_dat=%3Cproquest_doaj_%3E2783791502%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c417t-a8ff6c127c37f251f9a483490a0fce3815a3fac41055d9cc42c7c2697ae921eb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2783791502&rft_id=info:pmid/36874100&rfr_iscdi=true